JP2023036899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023036899A5 JP2023036899A5 JP2022211496A JP2022211496A JP2023036899A5 JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5 JP 2022211496 A JP2022211496 A JP 2022211496A JP 2022211496 A JP2022211496 A JP 2022211496A JP 2023036899 A5 JP2023036899 A5 JP 2023036899A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- antibody
- pharmaceutical composition
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218361A JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455245P | 2017-02-06 | 2017-02-06 | |
| US62/455,245 | 2017-02-06 | ||
| JP2019542388A JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| PCT/US2018/017027 WO2018145075A1 (en) | 2017-02-06 | 2018-02-06 | Compositions and methods for augmenting antibody mediated receptor signaling |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Division JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218361A Division JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023036899A JP2023036899A (ja) | 2023-03-14 |
| JP2023036899A5 true JP2023036899A5 (cg-RX-API-DMAC10.html) | 2023-10-03 |
| JP7606501B2 JP7606501B2 (ja) | 2024-12-25 |
Family
ID=63040120
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Active JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2022211496A Active JP7606501B2 (ja) | 2017-02-06 | 2022-12-28 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
| JP2024218361A Pending JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542388A Active JP7231549B2 (ja) | 2017-02-06 | 2018-02-06 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218361A Pending JP2025028191A (ja) | 2017-02-06 | 2024-12-13 | 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220213206A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3576793A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7231549B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110520158A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2018215673B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3049689A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018145075A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| RU2734432C1 (ru) * | 2019-04-23 | 2020-10-16 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с GITR |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| WO2022241182A1 (en) * | 2021-05-13 | 2022-11-17 | Arizona Board Of Regents On Behalf Of Arizona State University | A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer |
| CN115873126A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 人生长激素融合蛋白及其制备和用途 |
| CA3263665A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anti-CLDN4 antibodies and their methods of use |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912224A (en) * | 1996-02-22 | 1999-06-15 | The General Hospital Corporation | Methods and compositions for enhancing cellular response to TGF-β ligands |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| AU2015200990B2 (en) * | 2009-03-20 | 2016-07-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Optimized Fc variants |
| WO2014006217A1 (en) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| MX387324B (es) * | 2013-01-10 | 2025-03-18 | Genmab Bv | Variantes de regiones fc de igg1 de humano y usos de las mismas. |
| JP6636803B2 (ja) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| DK3189081T3 (da) * | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| PT3215528T (pt) * | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| CA2978501A1 (en) | 2015-03-05 | 2016-09-09 | Ucb Biopharma Sprl | Polymeric fc proteins and methods of screening to alter their functional characteristics |
| MX2017012805A (es) | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| EP3526257A2 (en) * | 2016-10-14 | 2019-08-21 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
| EP3535291A1 (en) * | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
-
2018
- 2018-02-06 WO PCT/US2018/017027 patent/WO2018145075A1/en not_active Ceased
- 2018-02-06 US US16/483,738 patent/US20220213206A1/en not_active Abandoned
- 2018-02-06 CA CA3049689A patent/CA3049689A1/en not_active Abandoned
- 2018-02-06 CN CN201880010285.3A patent/CN110520158A/zh active Pending
- 2018-02-06 AU AU2018215673A patent/AU2018215673B2/en active Active
- 2018-02-06 JP JP2019542388A patent/JP7231549B2/ja active Active
- 2018-02-06 EP EP18748152.8A patent/EP3576793A4/en active Pending
-
2022
- 2022-12-28 JP JP2022211496A patent/JP7606501B2/ja active Active
-
2023
- 2023-12-04 US US18/528,382 patent/US20240336694A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218361A patent/JP2025028191A/ja active Pending
-
2025
- 2025-04-22 AU AU2025202811A patent/AU2025202811A1/en active Pending